checkAd

     165  0 Kommentare TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO - Seite 3

    For more information, please contact:

    Lesen Sie auch

    TransCode Therapeutics, Inc.
    Tom Fitzgerald, Interim CEO; CFO
    tom.fitzgerald@transcodetherapeutics.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO - Seite 3 BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced …